Truly Translational Sweden AB
Truly Translational is a company dedicated to translating research into clinical success through drug development and business consultancy services. They focus on preclinical and early clinical drug development, with expertise in inflammation, oncology, respiratory diseases, and autoimmune diseases. Their mission is to help clients develop efficient experimental plans and conclusive clinical trials, leveraging almost 100 years of experience in pharmaceutical research and development.
Industries
Nr. of Employees
small (1-50)
Truly Translational Sweden AB
Malmo, Skåne County, Sweden
Products
Detection of Circulating Tumor Cells (research project)
Collaborative research project aiming to increase understanding of circulating tumor cells and the metastatic process, with the objective of developing methods for earlier cancer detection using imaging and analytical techniques.
IVD Performance Testing
IVD performance studies and laboratory testing services that produce reliable, well-documented datasets suitable for regulatory submissions and technical files under the IVDR.
IVDR‑Ready Performance Testing
Rigorous, well‑documented performance studies that meet the demands of the IVDR supporting analytical and clinical validation.
Flow Cytometry Services
Multi-parameter flow cytometry services providing critical data on biomarker expression, cell signalling, toxicity, and immune profiling to optimize drug candidates and support preclinical drug development.
Efficacy and Potency Evaluation Services
Preclinical drug development services evaluating the efficacy and potency of new compounds through in vitro and in vivo models.
Pharmacokinetic and Pharmacodynamic Services
Comprehensive preclinical pharmacokinetic and pharmacodynamic services including tailored study design, bioanalytical methods, in-house assay development, and noncompartmental analysis.
Detection of Circulating Tumor Cells (research project)
Collaborative research project aiming to increase understanding of circulating tumor cells and the metastatic process, with the objective of developing methods for earlier cancer detection using imaging and analytical techniques.
IVD Performance Testing
IVD performance studies and laboratory testing services that produce reliable, well-documented datasets suitable for regulatory submissions and technical files under the IVDR.
IVDR‑Ready Performance Testing
Rigorous, well‑documented performance studies that meet the demands of the IVDR supporting analytical and clinical validation.
Flow Cytometry Services
Multi-parameter flow cytometry services providing critical data on biomarker expression, cell signalling, toxicity, and immune profiling to optimize drug candidates and support preclinical drug development.
Efficacy and Potency Evaluation Services
Preclinical drug development services evaluating the efficacy and potency of new compounds through in vitro and in vivo models.
Pharmacokinetic and Pharmacodynamic Services
Comprehensive preclinical pharmacokinetic and pharmacodynamic services including tailored study design, bioanalytical methods, in-house assay development, and noncompartmental analysis.
Services
Consulting to develop strategic and operational plans from hypothesis through preclinical work to early clinical testing.
Support for design and coordination of preclinical in vitro and in vivo studies, pharmacology, PK/PD and safety evaluation planning.
Design of biomarker strategies, patient segmentation and personalized medicine approaches to inform early clinical trials.
Support for business development, alliance formation and commercialization planning across discovery and early clinical stages.
Drug development consultancy combined with access to external in vitro and in vivo laboratory capabilities, including inhalation pharmacology.
Consulting to develop strategic and operational plans from hypothesis through preclinical work to early clinical testing.
Support for design and coordination of preclinical in vitro and in vivo studies, pharmacology, PK/PD and safety evaluation planning.
Design of biomarker strategies, patient segmentation and personalized medicine approaches to inform early clinical trials.
Support for business development, alliance formation and commercialization planning across discovery and early clinical stages.
Drug development consultancy combined with access to external in vitro and in vivo laboratory capabilities, including inhalation pharmacology.
Expertise Areas
- Preclinical and early clinical development
- Translational medicine and biomarker strategy
- Pharmacology and DMPK/PK–PD
- Toxicology and safety assessment
Key Technologies
- In vivo pharmacology (animal models)
- In vitro assay development
- Biomarker assays and patient stratification
- Pharmacokinetic (PK) and PK–PD modelling
News & Updates
Marguérite pitching Truly Pharma's Methotrexate Forte project at Swiss Nordic Bio meeting in Zürich, February 7th 2019.
Truly Translational, in collaboration with Mensonides Pharmaceutical Technologies Consultancy, takes a next step in creating Truly Pharma. Focus remains on core business and proprietary projects.
Research project on early detection of cancer through circulating tumor cells, in collaboration with several universities and financed by the Knowledge Foundation.
Meet Truly Translational and Truly Labs at MVIS, October 12-13 in Lund.
Discussion on the importance of translational science in drug development, highlighting the company's experience since 2011.
Marguérite pitching Truly Pharma's Methotrexate Forte project at Swiss Nordic Bio meeting in Zürich, February 7th 2019.
Truly Translational, in collaboration with Mensonides Pharmaceutical Technologies Consultancy, takes a next step in creating Truly Pharma. Focus remains on core business and proprietary projects.
Research project on early detection of cancer through circulating tumor cells, in collaboration with several universities and financed by the Knowledge Foundation.
Meet Truly Translational and Truly Labs at MVIS, October 12-13 in Lund.
Discussion on the importance of translational science in drug development, highlighting the company's experience since 2011.